Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Imlunestrant in combination with Eli Lilly's Verzenio (abemaciclib) reduced the risk of progression or death by 43% versus imlunestrant alone, in all patients.On Wednesday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.
在週三，禮來（紐交所：LLY）公佈了針對雌激素受體陽性（ER+）、人類表皮生長因子受體2陰性、在先前的芳香化酶抑制劑治療後疾病進展的晚期乳腺癌的第3期EMBER-3研究的結果，該研究探索了imlunestrant的療效。
Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) as monotherapy in patients with an ESR1 mutation versus standard of care endocrine therapy (SOC ET), reducing the risk of disease progression or death by 38%.
與標準的內分泌治療（SOC ET）相比，imlunestrant在具有ESR1突變的患者中作爲單藥治療顯示出統計學顯著和臨床意義的無進展生存期（PFS）改善，將疾病進展或死亡的風險降低了38%。
Also Read: What's Going On With Eli Lilly Stock On Tuesday?
另請閱讀：禮來股票週二發生了什麼？
Imlunestrant in combination with Eli Lilly's Verzenio (abemaciclib) reduced the risk of progression or death by 43% versus imlunestrant alone, in all patients.
與禮來的Verzenio（abemaciclib）聯合使用時，imlunestrant在所有患者中將疾病進展或死亡的風險降低了43%，相比之下，單獨使用imlunestrant的效果較差。
Imlunestrant significantly improved progression-free survival versus standard-of-care endocrine therapy in patients with an ESR1 mutation.
在具有ESR1突變的患者中，imlunestrant顯著改善了無進展生存期，對比標準內分泌治療。
In patients with an ESR1 mutation, the median progression-free survival was 5.5 months with imlunestrant versus 3.8 months with standard-of-care endocrine therapy.
在具有ESR1突變的患者中，使用imlunestrant的中位無進展生存期爲5.5個月，而標準內分泌治療爲3.8個月。
The overall response rate (ORR) with imlunestrant was 14% compared to 8% with SOC ET in patients with an ESR1 mutation.
在具有ESR1突變的患者中，使用imlunestrant的總體反應率（ORR）爲14%，而標準內分泌治療（SOC ET）爲8%。
In all patients, the median PFS was 5.6 months with imlunestrant versus 5.5 months with standard-of-care endocrine therapy and did not reach statistical significance.
在所有患者中，使用imlunestrant的中位PFS爲5.6個月，而標準內分泌治療爲5.5個月，未達到統計學顯著性。
Imlunestrant-abemaciclib significantly improved PFS compared to imlunestrant in all patients, regardless of ESR1 mutation status, with median PFS of 9.4 months for imlunestrant-abemaciclib versus 5.5 months for imlunestrant alone.
Imlunestrant-abemaciclib與imlunestrant相比，在所有患者中顯著改善了無進展生存期（PFS），無論ESR1突變狀態如何，Imlunestrant-abemaciclib的中位PFS爲9.4個月，而imlunestrant單獨使用的中位PFS爲5.5個月。
In all patients, the ORR with imlunestrant-abemaciclib was 27% compared to 12% with imlunestrant alone.
在所有患者中，Imlunestrant-abemaciclib的客觀緩解率（ORR）爲27%，而單獨使用imlunestrant的客觀緩解率爲12%。
Overall survival (OS) results for EMBER-3 were immature at the time of analysis. The trial will continue to assess OS as a secondary endpoint.
EMBER-3的總體生存率（OS）結果在分析時尚不成熟。該試驗將繼續評估生存率作爲次要終點。
Imlunestrant is also being investigated in the adjuvant setting in people with ER+, HER2- early breast cancer with an increased risk of recurrence. This Phase 3 trial EMBER-4 is expected to enroll 6,000 patients.
Imlunestrant在ER+、HER2-早期乳腺癌的輔助治療中也正在研究，這些患者具有較高的復發風險。該3期試驗EMBER-4預計將招募6000名患者。
Price Action: LLY stock is down 1.20% at $790.01 at the last check on Wednesday.
價格動態：截至週三最後檢查時，LLY股票下跌1.20%，報790.01美元。
- Why Is Fertility Services Provider NewGenIvf Stock Rocketing On Wednesday?
- 爲什麼生育服務提供商NewGenIvf的股票在星期三大漲？
Photo via Shutterstock
照片來源於Shutterstock
譯文內容由第三人軟體翻譯。
